Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 4, 2003, Pages 303-306

  Haddad, Robert I ^a   Van Echo, David A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Docetaxel; Head and neck cancer; Topotecan

Indexed keywords

DOCETAXEL; TOPOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REGIMEN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS; TOPOTECAN;

EID: 0242361682     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0673-1     Document Type: Article

References (20)

1. Chen TT (1997) Optimal three-stage designs for phase II cancer clinical trials. Stat Med 16:2701-2711
2. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524
3. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521-526
4. Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, et al (1999) A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 81:457-462
5. Goldspiel BR (1997) Clinical overview of the taxanes. Pharmacotherapy 17(5 Pt 2):110S-125S
6. Goldwasser FL, Lemoine A, Gross M, et al (1999) Topotecan is a cytochrome P450-3A inhibitor: clinical and pharmacologic evidence (abstract 559). Proc Am Assoc Cancer Res 40:84
7. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics. CA Cancer J Clin 50:7-33
8. Haldar S, Basu A, Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233
9. Johnson RK, McCabe FL, Faucette LF, et al (1989) SK and F104864, a water soluble analog of camptothecin with a broad spectrum activity in preclinical tumor models (abstract 623). Proc Am Assoc Cancer Res 30
10. Jonsson E, Fridborg H, Nygren P, Larsson R (1998) Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 54:509-514
11. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302
12. Mendelsohn J, Shin DM, Donato N, et al (1999) A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC) (abstract 1502). Proc Am Soc Clin Oncol 18:289a
13. Robert F, Soong SJ, Wheeler RH (1997) A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. Am J Clin Oncol 20:298-302
14. Schoffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, et al (1999) Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10:119-122
15. Schrijvers D, Van Herpen C, Kerger J, et al (1999) Phase I-II study with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (abstract 614). Eur J Cancer [Suppl 4]35:S164
16. Smith RE, Lew D, Rodriguez GI, Taylor SA, Schuller D, Ensley JF (1996) Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study. Invest New Drugs 14:403-407
17. Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, et al (2000) Phase I study of docetaxel and topotecan in patients with solid tumors. Cancer Chemother Pharmacol 46:442-448
18. Tubiana-Mathieu N, Cupissol D, Calais G, et al (1999) Clinical results of docetaxel and 5-fluorouracil in metastatic/recurrent squamous cell carcinoma of the head and neck (abstract 604). Eur J Cancer 35 [Suppl 4]:S162
19. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) Head and neck cancer. New Engl J Med 328:184-194
20. Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, et al (2000) Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J Clin Oncol 18:3288-3294